New rules for OHIP coverage of out-of-Canada drug-administration services, with retroactive effect back to 2011

Plain-language summary · AI-assisted

Ontario's health insurance regulation now sets out a distinct pathway for covering services performed outside Canada that consist mainly of administering a drug. To qualify, the drug and its administration must be publicly funded in Ontario, access to the drug in Ontario must be temporarily unavailable, and the delay must create a risk of death or serious irreversible harm. A prior requirement for an executive-officer recommendation has been removed and replaced by these new conditions. Applications must now confirm that all of the new drug-related conditions are met, not just one from the old list. Critically, the change is retroactive to October 1, 2011, meaning past claims that relied only on the old recommendation pathway are no longer insured services—unless the General Manager issued written prior approval on or before October 6, 2026. Patients and providers who have pending or past claims for out-of-country drug administration should review whether those claims satisfy the new criteria.

Who this affects
Ontario residents with OHIP coverage seeking out-of-country drug treatment · physicians and specialists submitting out-of-country service applications · hospital and health facility operators outside Canada billing OHIP · patient advocates and health plan administrators managing prior approvals